Transgene: share price rises, trial authorized in France
At around 11:20 a.m., the biotech company's shares gained 4.7%, making it one of the biggest gainers on the CAC Mid & Small index, itself up 0.3%.
The company, which develops cancer immunotherapies based on viral vectors, has received authorization from France's Agence nationale de sécurité du médicament et des produits de santé (ANSM) to proceed with a Phase I trial on its proprietary oncolytic virus TG6050.
The drug candidate will be administered intravenously to patients with advanced non-small cell lung cancer (NSCLC).
TG6050 has been designed to express human IL-12, a cytokine known to trigger a powerful immune response, and a full-length anti-CTLA4 antibody.
Its antitumor response combines multiple mechanisms of action by selectively targeting cancer cells and expressing IL-12 and the anti-CTLA4 antibody in the tumor microenvironment.
The trial will include up to 36 patients with advanced-stage NSCLC relapsing after reference therapies, with inclusion of the first patient expected in the first half of 2023.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction